Ensysce Biosciences reports third quarter 2026 financial and clinical developments
Ensysce Biosciences completed a biopharma acquisition, advanced regulatory filings for its pain treatment pipeline, and ended the third quarter of 2026 with 29.7 million dollars in cash.
FTMQ Health, written by our newsroom1 view
Ensysce Biosciences announced its third quarter 2026 financial results and operational milestones on November 12, 2026, according to reports from TradingView and scanx.trade. The clinical-stage biotechnology company completed its acquisition of Cy Biopharma, which adds the lead candidate CY200 to its drug development pipeline for complex regional pain syndrome. TradingView and scanx.trade both reported on the company's quarter-end updates. [1][4]
TradingView reported that Ensysce Biosciences submitted a Phase 2a clinical protocol for CY200 to the UK Medicines and Healthcare products Regulatory Agency. In addition, the company finished participant enrollment in the final stage of its PF614-MPAR-102 study. According to scanx.trade, the company's third quarter revenue increased by 342 percent, while its net loss widened to 0.13 dollars per share. [1][4]
TradingView reported that the San Diego, California-based company ended the third quarter of 2026 with 29.7 million dollars in cash and cash equivalents. Other biotechnology firms, including Armata Pharmaceuticals and Assembly Biosciences, also announced their third quarter 2026 financial results on the same day, according to StreetInsider and Yahoo Finance. [1][2][3]
In short
- Ensysce Biosciences completed its acquisition of Cy Biopharma, acquiring the CY200 pipeline asset for complex regional pain syndrome.
- The company submitted a Phase 2a protocol for CY200 to the UK Medicines and Healthcare products Regulatory Agency.
- Ensysce Biosciences completed participant enrollment in the final stage of the PF614-MPAR-102 study.
- Ensysce Biosciences ended the third quarter of 2026 with 29.7 million dollars in cash and cash equivalents.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business HighlightsTradingView, 5d ago (the report this story comes from)
- [2]Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate UpdateStreetInsider, 5d ago
- [3]Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent UpdatesYahoo Finance, 5d ago
- [4]Ensysce Biosciences Q3 Results: Loss widens to $0.13, revenue jumps 342%scanx.trade, 5d ago
Background
- [5]List of largest biomedical companies by revenue on Wikipedia
- [6]Highlights (magazine) on Wikipedia
- [7]Experimental weight loss drug retatrutide reduces knee pain in trials FTMQ Health, 9d ago
- [8]BrightSpring Health Services raises 2026 outlook following third quarter earnings growth FTMQ Health, 10d ago
Our newsroom writes these reports with the help of software, from the 8 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Experimental weight loss drug retatrutide reduces knee pain in trialsMedical Science, 9d ago
- BrightSpring Health Services raises 2026 outlook following third quarter earnings growthHealth Care, 10d ago
More in Medical Science
- CAR T cell therapy analysis reveals high inflammation but low mortality5h ago
- Diets rich in dairy and fruit linked to child height growth1d ago
- Meningococcal B vaccine prompts immune responses against gonorrhea in trial2d ago
- RIPK1 Inhibitors Match Placebo Safety in Human Clinical Trials2d ago
- Frontiers in Psychiatry collection highlights music interventions for mental health3d ago
- Shanghai dismisses researchers after gene editing trial death3d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.